day at 4:30 p.m. ET. To access the call please dial 800-774-5358 U.S./Canada or 706-758-9475 International and enter passcode 20088902 or to listen to a live webcast and view accompanying slides, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com
. A replay of the call will also be available from 6:30 p.m. ET on July 20, 2009 until August 3, 2009 12:00 a.m. ET. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks after the call on the Idenix website.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184 or any other product candidate and any future clinical trials involving our product candidates and expectations with respect to additional milestone payments, future royalty payments, funding of
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Idenix Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results2
. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference3
. Idenix Pharmaceuticals Reports First Quarter Financial Results4
. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver5
. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference6
. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)7
. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results8
. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results9
. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference10
. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab11
. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results